Metastatic melanomas have extremely grave outcomes with median survival of around 6 months and a 5-year survival rate of 5 % ( 2,3 ). Th e most common cancers metastasizing to the adrenal glands are cancers of the lung and the gastrointestinal tract ( 8 ). In a study of nearly 6,000 malignant melanoma patients, metastases to the adrenal glands were seen in 13 % of patients and were associated with mortality rates of over 75 % ( 2 ).
Splenic Littoral Cell
To the Editor: Th e risk of malignancy in Crohn ' s disease (CD) has been well described. Moreover, immunomodulators, such as azathioprine (AZA) and 6-mercaptopurine (6-MP), and biological agents, such as infl iximab and adalimumab, may promote carcinogenesis ( 1 -3 ) . Splenic littoral cell tumors are recently described tumors of vascular origin composed of endothelial cells, with typical microscopic and immunohistochemical features of splenic sinus lining cells ( 4 ) . Clinical fi ndings are not specifi c, and outcome is unpredictable but usually benign, although a few cases with a malignant behavior have been reported ( 5, 6 ) .
We report a 58-year-old Caucasian man with a long history of ileocolonic CD. He had required multiple resections. He had been steroid dependent since 2002 and had received repeated antibiotics because of perianal abscesses. In June 2003, he received infl iximab (5 mg / kg) induction therapy, discontinued later on because of an infusion reaction. He was put on AZA (2 mg / kg / day), which was stopped owing to severe bone marrow toxicity, and was then put on 6-MP, which was withdrawn owing to liver and pancreatic enzyme alterations. In 2004, he had a severe relapse of perianal disease, which required multiple surgical drainages and local injections of infl iximab. In September 2009, he started adalimumab, which was again interrupted because of development of pancytopenia. Ten months later, the patient was admitted to our hospital because of diarrhea, abdominal pain, fever (40 ° C), fatigue, and active drainage of perianal fi stulas. Physical examination revealed a splenomegaly, but no peripheral palpable lymph nodes. Blood tests showed pancytopenia with severe anemia (hemoglobin level 7.8 g / dl), lymphocytopenia (white blood cell count 3,900 / μ l, lymphocytes 10 % ), and thrombocytopenia (platelets 67,000 / μ l). Evaluation for infectious agents was negative. Abdominal ultrasound and computerized tomography (CT) scan showed splenomegaly (22 cm long on its major axis) with multiple hypodense lesions; liver was normal. Previous abdominal imaging, available since 2002, did not show any organomegaly. During hospitalization, leukocytes went down to 770 / μ l. Bone marrow biopsy revealed a T-lymphocyte infi ltration (CD3 + ; CD2 + ; CD4 > CD8) not diagnostic for lymphoproliferative disease; splenectomy was performed. Th e spleen weighed 1,150 g. Macroscopically, the organ looked well capsulated, lacking signifi cant alteration. On histology, spleen parenchyma showed a slit-like anastomosing vascular proliferation with solid areas, with high proliferation index (Ki-67 + cells 25 % ) and spotty necrosis. On immunohistochemistry, the cell lining the vascular spaces showed coexpression of factor VIII and other endothelial line markers, as well as histiocytic line markers such as KP1. Th is phenotype was consistent with littoral cell diff erentiation ( Figures 1 -2 ) . Th e fi nal diagnosis was littoral cell hemangioendothelioma (HE). Laparotomic liver biopsy evidenced a normal liver architecture. Postoperative course was uneventful. Blood cell count went back to normal. Littoral cell HE is frequently associated with cancers in other visceral organs or malignant lymphoma, but total body CT scan, technetium bone scintigraphy, and positron emission tomography excluded neoplastic infi ltration of other organs.
In conclusion, our patient with a longstanding CD had a littoral splenic HE presenting with splenomegaly and hypersplenism. Th is presentation is not unusual: most cases of this tumor are asymptomatic ( > 55 % ) and are only discovered incidentally, but clinically splenomegaly is almost always present; abdominal pain, pyrexia of unknown origin, symptoms of hypersplenism (thrombocytopenia and anemia), and portal hypertension may occasionally be seen. He had received both immunomodulators and anti-tumor necrosis factor (TNF) agents and had experienced recurrent perianal abscesses, suggesting a possible promoting role of chronic infection and immunosuppression in the pathogenesis of this rare tumor, as suggested by other authors. Bi et al. ( 7 ) have noted that 17 % of the cases of littoral splenic HE were associated with immunological or congenital disorders, such as CD, Wiskott -Aldrich syndrome, Epstein syndrome, lymphocytic colitis, ankylosing spondylitis, Gaucher ' s disease, myelodysplastic syndrome, chronic glomerulonephritis, or aplastic anemia. To our knowledge, only one case of littoral HE in CD has been previously reported ( 8 ) . Our patient is the fi rst one to be exposed to the new anti-TNF agents. Cancer risk in patients treated with TNF-α antagonists is considered low, and a meta-analysis of randomized trials has found no diff erence between CD patients treated with biologics and controls ( 9 ) . Recently, the rare hepatosplenic T-cell lymphoma ( 3 ) has been described in young subjects, and another meta-analysis has confi rmed an increased risk of lymphoma related to anti-TNF therapy ( 10 ) . Lymphoma was our fi rst diagnostic hypothesis before splenectomy. Physicians caring for patients treated with biologics should be aware of the possibility of rarer tumors in the diff erential diagnosis of splenic focal lesions. On the basis of this case and previous reports on the occurrence of lymphoproliferative disorders and severe infections (tuberculosis) ( 11 ), we recommend regular follow-up abdominal ultrasound in the long-term monitoring of safety of anti-TNF agents.
